RO7589831 Werner helicase inhibitor shows efficacy in phase 1 trial
- A first-in-class targeted therapy known as a covalent Werner helicase inhibitor, designated as RO7589831, has shown early signs of efficacy and general tolerability in patients with advanced solid...
- Initial efficacy of the RO7589831 inhibitor was evaluated in 37 patients across multiple cancer types.
- The experimental agent belongs to a broader group of therapies that target the DNA damage response mechanism, functioning similarly to PARP inhibitors.
A first-in-class targeted therapy known as a covalent Werner helicase inhibitor, designated as RO7589831, has shown early signs of efficacy and general tolerability in patients with advanced solid tumors harboring specific genetic defects. According to phase I trial results presented on April 29, 2025, at the American Association for Cancer Research (AACR) Annual Meeting by Timothy Yap, the agent targets a critical DNA repair enzyme in tumors characterized by high microsatellite instability or mismatch repair deficiency.
Early Efficacy in Hard-to-Treat Tumors
Initial efficacy of the RO7589831 inhibitor was evaluated in 37 patients across multiple cancer types. Investigators reported that five of these patients achieved partial responses as determined by radiologic imaging, while 65.7% of all trial participants experienced lasting stable disease. Specialized metabolic imaging demonstrated that deeper metabolic responses correlated with both radiologic partial responses and longer-term disease control.
The clinical significance of these discoveries was emphasized by The University of Texas MD Anderson Cancer Center’s Timothy Yap, who serves as Professor of Investigational Cancer Therapeutics as well as Vice President and Head of Clinical Development in the Therapeutics Discovery Division. These are encouraging early clinical data, especially because this is a patient population that currently has very limited treatment options, stated Dr. Yap, adding that the results further validate Werner helicase as an actionable target given that many cancers are highly dependent on it for survival.
Mechanism of Action and Patient Selection
The experimental agent belongs to a broader group of therapies that target the DNA damage response mechanism, functioning similarly to PARP inhibitors. By inhibiting the function of the Werner helicase DNA repair enzyme, RO7589831 induces a buildup of DNA damage within tumor cells, which ultimately leads to cell death. Because normal cells do not harbor high microsatellite instability, the therapy is designed to spare healthy tissue.
These genetic defects occur across various cancer types. However, clinical data indicate that between 40% and 70% of patients with solid tumors exhibiting high microsatellite instability or mismatch repair deficiency either fail to respond to immune checkpoint inhibitors or develop resistance during treatment, leaving a significant unmet medical need.
Safety Profile and Dose Optimization
Safety assessments were conducted in 44 patients enrolled in the trial. The majority of participants experienced grade 1 or 2 adverse events, with higher doses appearing less tolerable than lower doses. The most common side effects reported were mild, manageable nausea, vomiting, and diarrhea, and no dose-limiting toxicities were observed during this phase of the study.
To establish the optimal recommended dose for subsequent evaluation, three randomized dose-level cohorts are currently underway. Funding for this phase I trial was provided by Roche.